Introduction
============

Lung cancer is the most common cancer in terms of incidence and mortality throughout the world, accounting for 13% of all cases and for 18% of deaths in 2008 ([@b10-2013-011]). In China, lung cancer rates are increasing because smoking prevalence continues to either rise or show signs of stability ([@b27-2013-011]; [@b11-2013-011]). Lung cancer is most often diagnosed at late stages, when it has already presented local invasion and distal metastases ([@b21-2013-011]). Therefore, the identification of early molecular events inherent to lung tumorigenesis is an urgent need, so as to provide a basis for intervention in carcinogenesis.

All cancers arise as a result of the acquisition of a series of fixed DNA sequence abnormalities, mutations, many of which ultimately confer a growth advantage to the cells in which they have occurred. Several mutated genes related to tumor growth, invasion or metastasis have been identified in lung cancer, and new agents that inhibit the activities of these genes have been developed, aiming to improve the outcome of lung cancer treatment ([@b3-2013-011]). Among these genes, *EGFR* (epidermal growth factor receptor) is frequently overexpressed in non-small-cell lung cancer (NSCLC) ([@b23-2013-011]). *EGFR* tyrosine kinase inhibitors (*e.g.* Gefitinib and Erlotinib) have been tested in trials for treating NSCLC ([@b6-2013-011]; [@b13-2013-011]; [@b7-2013-011]; [@b26-2013-011]; [@b14-2013-011]). Furthermore, *KRAS* and *TP53* gene mutations have been found in up to 30% of lung cancer cases and have been considered as predictive factors of poor prognosis ([@b9-2013-011]; [@b20-2013-011]; [@b18-2013-011]).These frequently mutated genes can be used to design kits for early detection of carcinogenesis. For example, a kit from Life Technologies Corporation (Ion Ampli Seq^™^) was designed to detect 739 COSMIC mutations in 604 loci from 46 oncogenes and tumor suppressor genes, with emphasis on the deep coverage of genes *KRAS*, *BRAF* and *EGFR* for the detection of somatic mutations in archived cancer samples.

In this study, we analyzed the latest data on lung cancer, aiming to identify frequently mutating genomic "hotspot" regions in human lung cancer genes. The results are significant and promising, once the ability to identify the actual sequence of mutations may help determining which mutations lead to precancerous lesions and which produce invasive carcinomas. Thus, our study may contribute to improve lung cancer diagnosis and design better prognosis kits.

Materials and Methods
=====================

Database of somatic mutations in cancer
---------------------------------------

The COSMIC (Catalogue of Somatic Mutations in Cancer) database ([@b5-2013-011]) was designed to store and display somatic mutation information and related details and contains information on human cancers. The current release (v64) describes over 913,166 coding mutations of 24,394 genes from almost 847,698 tumor samples. To construct a complete dataset of cancer mutation information, we had to start by finding a complete catalogue of gene mutations in lung cancer patients. Therefore, we downloaded somatic mutation data from the COSMIC database. All genes selected for the COSMIC database came from studies in the literature and are somatically mutated in human cancer ([@b1-2013-011]). Based on this authority resource, we constructed a complete dataset of cancer mutation information for the analysis described in the following.

Lung cancer mutation extraction
-------------------------------

As our aim was to collect data on lung cancer, we searched for mutation information in the web-software BioMart Central Portal. BioMart offers a one-stop shop solution to access a wide array of biological databases, such as the major biomolecular sequence, pathway and annotation databases such as Ensembl, Uniprot, Reactome, HGNC, Wormbase and PRIDE ([@b8-2013-011]). We used the Cancer BioMart web-interfere, with the following criteria: 1. Primary site = "lung"; 2. Mutation ID is not empty. The first criterion ensures that the mutation occurs in lung tissues, and the second criterion helps excluding the samples without mutation in a specific gene. Thereby we obtained the list of mutations in lung cancer.

Mutation frequency calculation
------------------------------

In order to identify the most important mutated genes in lung cancer, we calculated the mutation frequency for each mutated gene. In this calculation, we considered the same sample used in different experiments as a different sample. For example, if a gene *AKT1* mutation was found in two different experiments, gene *AKT1* was assigned a mutation frequency of 2, even if both experiments were performed with samples from the same tissue of the same patient. Sometimes, frequencies are presented as percentages. In this study, however, we did not divide the frequency of 2 by the whole sample, because we focused only on how common the mutation is and how many of these mutations were identified. For example, if the mutation percentage was 100%, but the number of samples with the mutation was only 3, this gene was not accepted in our diagnostic kit.

Protein-Protein Interaction (PPI) network
-----------------------------------------

The number of mutation events in the list of lung cancer mutations is very high, but some of these mutations are not found in lung cancer only. So, in order to find the key genes of this list, we analyzed the relationship between those genes. We started with the intent of using KEGG for digging into these relations. However, KEGG shows the very putative gene in a specific biological pathway, and there are many genes which cannot be located in the accurate site in some pathways. For the past few years, PPI databases have become a major tool for digging into biological relations. The great protein-protein interaction source offers a possible way of guessing their function through the interacted protein. If an interacted gene has a lung-regulated mechanism, the anchor gene will always show a similar function. Then, if all genes inputted to PPI have similar functions, there will be a regulation network among them.

As there are so many public PPI databases and each database has its own features, we combined the following databases, introduced by a former paper ([@b17-2013-011]): HPRD, IntAct, MIPS, BIND, DIP, MINT, PDZBase and Reactome. Genes of the mutation list were mapped to these PPI databases and a PPI network was constructed. Thereafter, we found that some genes were isolated from the main network and could exclude them from our list of candidate genes for lung cancer. With this combined database, we were able to narrow down our lung cancer candidate gene list as much as possible.

Results
=======

The most complete catalogue of lung cancer mutation data
--------------------------------------------------------

Using the methods described above, we obtained a complete list of lung cancer mutations (data not shown) comprising a total of 21,135 mutation events. To our best knowledge, this is the most complete and detailed catalogue of mutation events associated with lung cancer. Almost all the 21,135 listed events are somatic mutations, with only two exceptions: mutation c.1334_1335ins17 in gene *FLCN* is a confirmed germline mutation, and mutation c.1579_1580GG \> CT in gene *SF3B1* is a nonspecified type of mutation. To obtain a profile of the mutation type distribution in lung cancer, we calculated the statistical frequency of each mutation type, presented in [Figure 1](#f1-2013-011){ref-type="fig"}, showing that there are many mutation subtypes, such as missense, nonsense, deletions and insertions. Among them, the missense mutations accounted for the largest proportion (61%).

Calculation of mutation frequency in lung cancer
------------------------------------------------

The gene mutation list contains 21,135 mutation events related to 20,906 unique samples. In order to screen the most important mutated genes, we calculated the mutation frequency of each gene in the list. [Figure 2](#f2-2013-011){ref-type="fig"} illustrates the top 23 genes found in lung cancer, clearly showing that the most frequently mutated genes in lung cancer are *EGFR*, *KRAS* and *TP53*, with a mutation frequency of 10957, 3106 and 2034, respectively. Next, the mutation events in each gene were sorted ([Figure 3](#f3-2013-011){ref-type="fig"}), this showing that the mutation type of each gene varies dramatically, even in the top 23 mutated genes. As shown in [Figure 3](#f3-2013-011){ref-type="fig"}, gene *TP53* was the one with the largest number of mutation types, amounting to more than ten times the number of mutation types of *KRAS*, although the mutation frequency of *KRAS* was higher than that of *TP53*.

Construction of the PPI network
-------------------------------

By mapping the mutated genes into PPI databases, we constructed a PPI network, shown in [Figure 4](#f4-2013-011){ref-type="fig"}. For a deep data-mining of this network, we calculated the interaction weight (numbers of neighbors) of each core node and visualized the relationships of weight and mutation event for each gene ([Figure 5](#f5-2013-011){ref-type="fig"}). Analyzing [Table 1](#t1-2013-011){ref-type="table"} and [Figure 5](#f5-2013-011){ref-type="fig"}, it becomes evident that genes with high mutation frequencies also had higher interaction weights. For example, the top 3 mutated genes *EGFR*, *KRAS* and *TP53* also had higher interaction weights: 32, 37 and 41, respectively. On the other hand, we noticed that some genes with relative lower mutation frequencies were the core nodes in the PPI network. For example, AKT1 has a high PPI weight (41) but a low mutation frequency (6).

Candidate genes for sequencing kits
-----------------------------------

After mining the COSMIC database and analyzing the lung cancer PPI network, we screened the most important mutated genes in lung cancer based on one of the following criteria: PPI weight \> 7 and mutation frequency \> 5. After selection, 145 genes meeting the cutoff criteria were screened out ([Table 2](#t2-2013-011){ref-type="table"}). We consider that these mutated genes could be used to design sequencing kits for diagnostic purposes.

Discussion
==========

Many researchers have attempted to find a complete mutation profile of each cancer. In this study, we obtained a list of lung cancer mutations totaling 21,135 mutation events. We believe that to this date this list is the most complete and detailed catalogue of lung cancer mutation events available. Mutations from Stage I to Stage II, from cell line to biopsy, from small cell carcinoma to NSCLC, were almost all included in this list.

As expected, by calculating the mutation frequency for each gene in this list, *EGFR*, *KRAS* and *TP 53* were found to be the top 3 most frequently mutated genes in lung cancer. In addition, these three genes were the hub nodes in the PPI network. *EGFR* and *KRAS* have been proved to be lung cancer oncogenes for years. An investigation done in 2004 on the gefitinib therapy effect found somatic mutations of *EGFR* in 15 of 58 unselected tumors from Japan and in one out of 61 from the United States ([@b19-2013-011]). *EGFR* has since been accepted as a target for lung cancer therapy, and *EGFR* mutations may predict sensitivity to gefitinib. In recent years, developing *EGFR* mutations into a diagnostic target has been a research hotspot. In 2008, [@b15-2013-011] used molecular characterization of circulating tumor cells as a strategy for noninvasive serial monitoring of tumor genotypes during treatment. It is known that most lung adenocarcinoma-associated *EGFR* mutations confer sensitivity to specific *EGFR* tyrosine kinase inhibitors. [@b22-2013-011] found that *EGFR* exon 19 insertion mutations are also sensitive to this class of drugs. All these findings suggest that lung cancer patients should be tested for *EGFR* mutations.

After *EGFR*, the second most important gene in the development of lung cancer is *KRAS*. As early as in 2001, [@b12-2013-011] found that mice carrying *KRAS* mutations were highly predisposed to a range of tumor types, predominantly early-onset lung cancer. Furthermore, mutations of *KRAS* and *EGFR* can be combined to predict prognosis. For example, [@b16-2013-011] found that patients with both *EGFR* mutation and increased *EGFR* copy number had a \> 99.7% chance of objective response to EGFR-TKI therapy, whereas patients with *KRAS* mutation with or without increased *EGFR* copy number had a \> 96.5% chance of disease progression. They concluded that the *KRAS* mutation should be included as an indicator of resistance in the panel of markers used to predict response to EGFR-TKI lung cancer therapy. Based on the fact that these core genes in the PPI network are strongly related to lung cancer, we believe that this PPI network contains the most important genes related to lung cancer.

Many companies detect lung cancer by only four somatic gene mutations (*EGFR*, *KRAS*, *BRAF* and *PI3K*). As expected, these genes are all included in our list ([Table 2](#t2-2013-011){ref-type="table"}; mutation frequency of *BRAF* = 130, weight = 25; mutation frequency of *PI3K3A* = 93, weight = 48). *BRAF* encodes a RAS-regulated kinase that mediates cell growth and the activation of the malignant transformation kinase pathway ([@b25-2013-011]). [@b2-2013-011] found that *BRAF* mutations in human lung cancers may identify a subset of tumors sensitive to targeted therapy. Furthermore, an in vivo study with the inhibitor of the last of the four genes, *PI3K*, aimed at testing its activity in lung cancer treatment ([@b4-2013-011]), this leading to the conclusion that inhibitors of the PI3K-mTOR pathway may be activated in cancers with *PIK3CA* mutations and, when combined with MEK inhibitors, may effectively treat *KRAS* mutated lung cancers.

As *EGFR* and *KRAS* kits are widely used, we listed our *EGFR* and *KRAS* mutation events in [Tables 3](#t3-2013-011){ref-type="table"} and [4](#t4-2013-011){ref-type="table"}. In these tables, we sorted the mutations in *EGFR* and *KRAS* by frequency, with "Y" meaning the typical mutation used in the detection kits supplied by many companies; and "-" meaning that the mutation has a location in the genome similar to some of the other detected mutations. But, first of all, "-" is an alert to the fact that there are many different kinds of mutation in the same region. Traditional methods such as PCR are unable to detect such complicated mutations. This is the first advantage that a Next-Generation Sequencing (NGS) technology can offer. Secondly, it is obvious that the frequent mutations represent a high percentage in the three kits and, on the other hand, many mutations with frequencies below 30 are not listed in the three kits. The cost of detecting more than 100 mutations at the same time by PCR is very high, conferring NGS another advantage over PCR detection.

It is really urgent to develop a NGS kit for detecting lung cancer mutations. Our genes for the sequencing kit can be designed for somatic mutation detection. The 145 gene set comprises all of the somatic mutation detecting purpose genes - *EGFR*, *KRAS*, *BRAF* and *PIK3CA* ([@b24-2013-011]) - and may provide a feasible choice for a NGS kit. With the progresses in sequencing technology, mutations in lung cancer patients can be detected in one day or even less time. This technology applied to cancer genome sequencing can speed up cancer research, and the kit for diagnostic or recurrence evaluation should be introduced in clinical care as soon as possible, in order to offer patients a better chance of less suffering and a higher survival perspective.
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![Mutation types in lung cancer genome. Mutation types included three major types: substitution, deletion and insertion. Each of the major mutation types was categorized into frameshift mutation or in-frame mutation. The latter, although not causing a shift in the triplet reading frame, can, however, lead to the encoding of abnormal protein products.](2013-011-fig1){#f1-2013-011}

![Top 23 most frequently mutated genes in lung cancer. The X-axis represents the top 23 genes and labels are the gene symbols. The Y-axis reflects the total amount of mutation events occurred in these genes.](2013-011-fig2){#f2-2013-011}

![Types of mutations in the top 23 most frequently mutated genes in lung cancer. The X-axis represents the top 23 genes and labels are the gene symbols. The Y-axis reflects the number of mutation types occurred in the corresponding genes.](2013-011-fig3){#f3-2013-011}

![Protein-protein interaction (PPI) network for somatic mutations in lung cancer genes (genes which have no relationship with this main network are not shown).](2013-011-fig4){#f4-2013-011}

![PPI core genes showing number of neighbor genes *vs.* somatic mutation frequency. Each dot represents a lung cancer gene; genes with more than 10 neighbors or with more than 10 COSMIC somatic mutation events are shown.](2013-011-fig5){#f5-2013-011}

###### 

Protein-protein interaction (PPI) network core genes, listed by gene symbol, weigh and mutation frequency.

  Gene      Weight   Mutation frequency   Gene       Weight   Mutation frequency
  --------- -------- -------------------- ---------- -------- --------------------
  PIK3CA    48       93                   TYK2       7        5
  AKT1      41       6                    EPHB1      6        10
  TP53      41       2034                 ITPR1      6        7
  HRAS      39       9                    MLL        6        7
  CTNNB1    37       34                   APLNR      5        5
  KRAS      37       3106                 FGFR4      5        9
  PTEN      36       62                   IRAK2      5        5
  NRAS      34       33                   KIAA1804   5        5
  EGFR      32       10957                PIK3C3     5        8
  PTPN11    32       6                    PTCH2      5        6
  MTOR      31       6                    ROS1       5        8
  CBL       30       10                   TLR4       5        10
  PIK3CG    29       16                   ABL2       4        7
  ABL1      27       5                    AKAP9      4        5
  CDKN2A    26       310                  CDH11      4        10
  ERBB2     26       83                   EPHA5      4        19
  RB1       26       90                   EPHA7      4        8
  BRAF      25       130                  EPHB6      4        8
  NOTCH1    24       17                   FBXW7      4        14
  IRS1      22       5                    GRM1       4        8
  NF1       21       28                   ITPR3      4        5
  SMAD4     21       11                   NRG3       4        5
  CREBBP    19       6                    NTRK2      4        11
  PDGFRA    19       16                   PAK3       4        6
  BRCA2     18       7                    ADAMTSL3   3        5
  JAK2      18       5                    EPHB3      3        5
  KIT       18       11                   ITK        3        12
  STK11     18       172                  KEAP1      3        12
  LPHN3     17       15                   NCOA2      3        6
  FGFR2     15       11                   NFE2L2     3        44
  LRP1B     15       17                   NLRP3      3        8
  MAP2K4    15       7                    NOTCH3     3        8
  JAK3      14       5                    P2RY8      3        5
  KDR       14       16                   RUNX1T1    3        9
  MET       14       44                   TLN1       3        7
  RET       14       9                    CDC42BPA   2        6
  BAI3      13       27                   DNER       2        5
  EPHA3     13       17                   HECW1      2        6
  FLT3      13       7                    HERC1      2        5
  NTRK1     13       9                    INHBA      2        5
  PTCH1     13       6                    INSRR      2        11
  TERT      13       7                    LTK        2        6
  ATM       12       22                   NTRK3      2        20
  FLT1      12       10                   PAK6       2        5
  GRM8      12       15                   PIK3C2G    2        8
  FLT4      11       7                    RBL1       2        5
  ALK       10       16                   CCKBR      1        5
  ERBB4     10       20                   CSMD3      1        11
  MEN1      10       9                    HEPH       1        5
  MSH6      10       7                    KIAA1618   1        2
  APC       9        19                   LATS1      1        5
  EVI1      9        1                    LMTK2      1        8
  HYRC      9        1                    NPY5R      1        6
  SMARCA4   9        26                   PAK7       1        11
  NOTCH2    8        10                   PKHD1      1        15
  NOTCH4    8        8                    PPP1R3A    1        9
  PTPRD     8        14                   ROR2       1        8
  EPHA4     7        5                    TBX22      1        7
  GLI3      7        11                   TTN        1        15

###### 

Genes with high mutation frequency in lung cancer (n = 145).

  Gene symbol             Gene symbol         Gene symbol               Gene symbol             Gene symbol
  ----------------------- ------------------- ------------------------- ----------------------- -----------------------
  EVI1                    EPHA3               CBL                       MAP2K4                  PDIA4
  HYRC                    UBR5                RUNX1T1_ENST00000265814   ITPR1                   PAK6
  EGFR                    PIK3CG              RUNX1T1                   FLT4                    P2RY8
  KRAS                    PDGFRA              RET                       FLT3                    NRG3
  TP53                    KDR                 PPP1R3A                   BRCA2                   MECOM
  CDKN2A                  ALK                 NTRK1                     ABL2                    LMTK3
  STK11                   TTN                 MEN1                      USP29                   LATS1
  BRAF                    PKHD1               KSR2                      RNF213                  KIAA1804
  PIK3CA                  LPHN3               HRAS                      PTPN11                  JAK3
  RB1                     GRM8                FGFR4                     PTCH2                   JAK2
  ERBB2                   PTPRD               ROS1                      PTCH1                   ITPR3
  PTEN                    FBXW7               ROR2                      PAK3                    IRS1
  NFE2L2                  KEAP1               PIK3C3                    NPY5R                   IRAK2
  MET                     ITK                 PIK3C2G                   NCOA2                   INHBA
  CTNNB1                  SMAD4               NOTCH4                    MTOR                    HERC1
  CDKN2a(p14)             PAK7                NOTCH3                    MKRN3                   HEPH
  NRAS                    NTRK2               NLRP3                     MERTK                   FBXO10
  MUC16                   KIT                 MYO3B                     LTK                     ERCC6
  NF1                     INSRR               LMTK2                     HECW1                   EPHB3
  BAI3                    GLI3                GRM1                      FLT4_ENST00000261937    EPHA4
  SMARCA4                 FGFR2               EPHB6                     DOCK3_ENST00000266037   DNER
  MUC16_ENST00000331986   CSMD3               EPHA7                     CREBBP                  DGKB
  ATM                     TLR4                ENSG00000121031           CDC42BPA                CCKBR
  NTRK3                   PRKDC               TLN1                      AKT1                    BAI2
  ERBB4                   NOTCH2              TERT                      ZMYM2_ENST00000456228   APLNR
  EPHA5                   FLT1                TBX22                     VEGFC                   ANKK1
  APC                     FBXW7_NM_018315_2   TAF1L                     TYK2                    AKAP9_ENST00000356239
  NOTCH1                  EPHB1               MSH6                      ROBO2                   AKAP9
  LRP1B                   CDH11               MLL                       RBL1                    ADAMTSL3

###### 

Mutation events for *EGFR* mutation kits.

  Mutation in *EGFR*                          Mutation frequency
  ------------------------------------------- --------------------
  L858R                                       2688
  c.2573T \> G:L858R                          1378
  E746_A750del                                955
  c.2235_2249del15:E746_A750del               609
  T790M                                       346
  c.2236_2250del15:E746_A750del               326
  c.2240_2257del18:L747_P753 \> S             113
  c.2369C \> T:T790M                          102
  L747_P753 \> S                              81
  c.2239_2248TTAAGAGAAG \> C:L747_A750 \> P   72
  L861Q                                       70
  L747_T751del                                58
  c.2237_2255 \> T:E746_S752 \> V             47
  L747_A750 \> P                              47
  G719S                                       45
  c.2240_2254del15:L747_T751del               43
  c.2582T \> A:L861Q                          39
  G719A                                       36
  L747_S752del                                36
  S768I                                       34
  c.2239_2256del18:L747_S752del               31
  c.2155G \> A:G719S                          24
  c.2156G \> C:G719A                          24
  L747_P753del                                24
  E746_S752 \> V                              23
  c.2155G \> T:G719C                          20
  c.2239_2253del15:L747_T751del               20
  E746_T751del                                20
  c.2239_2251 \> C:L747_T751 \> P             19
  c.2303G \> T:S768I                          19
  c.2237_2251del15:E746_T751 \> A             18
  G719?                                       16
  c.2239_2247del9:L747_E749del                15
  c.2497T \> G:L833V                          15
  G719C                                       14
  L747_A750del                                13
  L747_T751 \> P                              13
  c.2125G \> A:E709K                          12
  D770_N771insSVD                             12
  L747_P753 \> Q                              12
  E746_T751 \> A                              11
  P772_H773insPR                              11
  c.2126A \> C:E709A                          10
  H773R                                       7
  R776H                                       7
  c.2233_2247del15:K745_E749del               6
  c.2238_2252del15:L747_T751del               6
  c.2254_2277del24:S752_I759del               6
  c.2582T \> G:L861R                          6
  H773_V774insNPH                             6
  L833V                                       6
  c.2126A \> G:E709G                          5
  c.2237_2253 \> TTGCT:E746_T751 \> VA        5
  c.2237_2256 \> TT:E746_S752 \> V            5
  c.2253_2276del24:S752_I759del               5
  c.2311_2312ins9:D770_N771insSVD             5
  c.2319_2320ins9:H773_V774insNPH             5
  c.2504A \> T:H835L                          5
  c.2543C \> T:P848L                          5
  c.89_889del801:V30_R297 \> G                5
  K745_A750del                                5
  L747_T751 \> S                              5
  L747P                                       5
  L861R                                       5
  V843I                                       5

###### 

Mutation events for *KRAS* mutation kits.

  Mutation in *KRAS*               Mutation frequency
  -------------------------------- --------------------
  c.34G \> T:G12C                  1273
  c.35G \> T:G12V                  625
  c.35G \> A:G12D                  524
  c.35G \> C:G12A                  202
  c.34G \> A:G12S                  139
  c.37G \> T:G13C                  99
  c.38G \> A:G13D                  76
  c.34G \> C:G12R                  69
  c.34_35GG \> TT:G12F             22
  c.183A \> T:Q61H                 13
  c.182A \> T:Q61L                 12
  c.183A \> C:Q61H                 10
  Q61H                             10
  c.182A \> G:Q61R                 9
  G12D                             9
  c.181C \> A:Q61K                 6
  c.37G \> A:G13S                  6
  c.181C \> G:Q61E                 4
  c.37G \> C:G13R                  3
  G12F                             3
  c.182A \> C:Q61P                 2
  c.198_199ins15:A66_M67insEEYSA   2
  c.34_35GG \> CT:G12L             2
  c.35_36GT \> AA:G12E             2
  c.38_39GC \> TT:G13V             2
  G12A                             2
  G12C                             2
  G12V                             2
  L19F                             2
  c.15AT:K5N                       1
  c.180_181TC \> CA:Q61K           1
  c.205delG:D69fs\*4               1
  c.27T \> C:V9V                   1
  c.31G \> C:A11P                  1
  c.32C \> T:A11V                  1
  c.34_36GGT \> TGC:G12C           1
  c.35_36GT \> TC:G12V             1
  c.35delG:G12fs\*3                1
  c.36T \> C:G12G                  1
  c.38G \> C:G13A                  1
  c.38G \> T:G13V                  1
  c.52G \> A:A18T                  1
  c.53C \> A:A18D                  1
  G12_G13insG                      1
  G12S                             1
  G13D                             1
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